ArticleBMC veterinary research2026
Molecular prevalence and clinical profiles of canine babesiosis in northern India.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCanine babesiosis is a significant and emerging tick-borne disease caused by Babesia spp. This study investigated the molecular prevalence, hematobiochemical profiles, and risk factors for B. vogeli and B. gibsoni infections in dogs in northern India, addressing the molecular research on babesiosis prevalence in this region.
resultsAn overall prevalence of canine babesiosis by microscopy and PCR was 12.5% (27/216) and 27.78% (60/216), respectively. The prevalence rates for B. vogeli by microscopy and conventional PCR were 10.64% and 22.22%, respectively, whereas the corresponding rates for B. gibsoni were 1.85% and 5.55%, respectively. Results revealed that B. vogeli was the predominant species. Non-descript dogs were significantly more susceptible to B. vogeli infection (OR: 27.491; 95% CI: 1.092-692.018; P < 0.05). Additionally, dogs with enlarged lymph nodes were three times more likely to be B. vogeli-positive (OR = 3.338; 95% CI: 1.345-8.287; P < 0.05). Dogs under one year had higher odds of B. vogeli infection, but this was not statistically significant (OR = 1.765; 95% CI: 0.663-4.703). Similarly, B. gibsoni infection was associated with dogs over four years old (P < 0.001) and males (P < 0.05). Vital parameters (temperature, pulse rate, and respiration rate) showed no significant association with B. vogeli and B. gibsoni infections. Hematological parameters, viz., hemoglobin (Hb), total erythrocyte count (TEC), packed cell volume (PCV), and platelet count, were significantly decreased in both B. vogeli and B. gibsoni affected dogs (P < 0.05). Babesia gibsoni-infected dogs had significantly lower TEC, PCV, and platelet count than B. vogeli-infected dogs. Biochemical parameters, viz., alanine aminotransferase (ALT), total bilirubin (TB), direct bilirubin (DB), indirect bilirubin (IDB), and blood urea nitrogen (BUN), were significantly increased, with decreased albumin levels (P < 0.05). Babesia gibsoni-infected dogs had significantly higher BUN, TB, and IDB levels than B. vogeli-infected dogs. Treatment was based on the Babesia species, with imidocarb dipropionate for B. vogeli and a combination therapy (diminazene aceturate, imidocarb dipropionate, and clindamycin) for B. gibsoni, which showed promising efficacy.
conclusionsThe study highlighted the importance of accurate diagnosis and species-specific treatment for canine babesiosis, with B. vogeli being more prevalent (22.22%) than B. gibsoni (5.55%), and distinct risk factors and clinical implications for each Babesia species in northern India. These findings contribute to the understanding of Babesia epidemiology in the region and highlight the need for further studies to inform the development of targeted control strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.